Loading...
Market
Will Novo Nordisk publish Phase 3 trial results for Liraglutide (Victoza) in a peer-reviewed journal by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Peer-reviewed medical journals and Novo Nordisk press releases
Story
Novo Nordisk's GLP-1 Drug Liraglutide (Victoza) Shows Potential in Slowing Alzheimer's Progression
Jul 30, 2024, 11:14 AM
Novo Nordisk's older GLP-1 drug, liraglutide, commonly used for managing diabetes and weight loss, appears to slow cognitive decline in Alzheimer's patients. According to Phase 2b clinical trial data presented at the Alzheimer's Association International Conference 2024, the drug may protect the brain and slow disease progression. The study, published on Tuesday, showed that liraglutide, known commercially as Victoza, yielded mixed results in a small mid-stage study but indicated a potential to slow the loss of brain volume in people with mild Alzheimer's disease.
View original story
Similar markets
Yes • 50%
No • 50%
Exceeds expectations • 25%
Meets expectations • 25%
Falls short of expectations • 25%
Trial cancelled • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No action taken • 25%
Safety label update • 25%
Product recall • 25%
Other regulatory actions • 25%
Focus on improving CagriSema • 25%
Develop a new obesity drug • 25%
Increase investment in marketing existing drugs • 25%
Pursue mergers or acquisitions • 25%
